Abaloparatide (Tymlos): Uses, Evidence, and Side Effects

Key takeaways

• Abaloparatide is FDA-approved under the brand name Tymlos for osteoporosis in postmenopausal women and in men at high fracture risk.
• It works by activating the PTH1 receptor, stimulating new bone formation on both trabecular and cortical surfaces.
• More than two dozen registered trials have studied abaloparatide, including work on fracture healing and sequencing with other osteoporosis treatments.
• The most frequently reported reactions in FDA adverse event data are headache, nausea, and dizziness.
• Abaloparatide does not carry a boxed warning.

What abaloparatide is

Abaloparatide is a laboratory-made analog of parathyroid hormone related peptide, or PTHrP(1-34). It belongs to the class of parathyroid hormone related peptide analogs. The drug acts as an agonist at the PTH1 receptor, which turns on cAMP signaling inside bone-forming cells. Daily activity at this receptor encourages osteoblasts, the cells responsible for building bone, to increase activity on both the trabecular (spongy) and cortical (dense) surfaces of bone.

What abaloparatide is approved for

Tymlos is approved for postmenopausal women with osteoporosis who are at high risk for fracture, defined as a history of an osteoporotic fracture or the presence of multiple fracture risk factors. It is also approved for women and men who have not responded to, or cannot tolerate, other available osteoporosis therapies. In men, Tymlos is approved to increase bone density when osteoporosis carries a high fracture risk. No boxed warning is listed on the label.

What the evidence shows

Abaloparatide has been studied across 26 registered clinical trials. One completed Phase 2 trial examined abaloparatide's effect on healing after pelvic fracture. A Phase 3 trial, PBK_L2201, has been evaluating efficacy and safety in postmenopausal women with osteoporosis, though its current status is listed as unknown. A separate, actively recruiting trial is examining sequential therapy strategies following osteoanabolic treatment like abaloparatide.

Reported side effects

Adverse event reports submitted to the FDA reflect counts of reported reactions, not confirmed incidence or proven causation. The most commonly reported reactions are neurological and gastrointestinal: headache (4,238 reports), nausea (3,281), and dizziness (3,185). Fatigue and cardiovascular symptoms such as increased heart rate and palpitations also appear frequently, alongside joint pain (arthralgia). A notable share of reports involve dose omission issues rather than a specific physical symptom.